From January 1, 2024 to March 31, 2024, the company has repurchased 409,700 shares, representing 0.1% for CNY 5.13 million. With this, the company has completed the repurchase of 1,161,200 shares, representing 0.29% for CNY 15.39 million under the buyback announced on November 16, 2023.
Shanghai Labway Clinical Laboratory Co., Ltd
Equities
301060
CNE100004RG8
Healthcare Facilities & Services
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.26 CNY | -2.66% | -7.23% | -22.80% |
1st Jan change | Capi. | |
---|---|---|
-22.80% | 568M | |
-15.96% | 8.57B | |
+67.50% | 4.3B | |
-4.03% | 2.46B | |
-42.54% | 2.31B | |
-6.49% | 1.93B | |
-20.45% | 1.53B | |
-41.24% | 1.2B | |
+10.26% | 1.14B | |
+18.74% | 986M |
- Stock Market
- Equities
- 301060 Stock
- News Shanghai Labway Clinical Laboratory Co., Ltd
- Tranche Update on Shanghai Labway Clinical Laboratory Co., Ltd's Equity Buyback Plan announced on November 16, 2023.